argenex (NASDAQ:ARGX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

argenex (NASDAQ:ARGX) had its price objective increased by investment analysts at Royal Bank Of Canada from $945.00 to $1,025.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target points to a potential upside of 11.63% from the stock’s previous close.

ARGX has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $940.00 price objective on shares of argenex in a report on Thursday, June 25th. Wedbush reissued an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a research note on Thursday, June 11th. Citizens Jmp dropped their price target on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating for the company in a research report on Friday. Wells Fargo & Company raised their price target on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research note on Monday, June 1st. Finally, Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,050.50.

argenex Price Performance

Shares of ARGX stock opened at $918.22 on Friday. The stock has a market cap of $57.44 billion, a P/E ratio of 35.26, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45. argenex has a one year low of $587.37 and a one year high of $953.58. The stock has a fifty day moving average price of $868.28 and a 200 day moving average price of $815.12.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The firm had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 70.27%. Equities research analysts anticipate that argenex will post 26.95 EPS for the current year.

Institutional Investors Weigh In On argenex

Institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC grew its holdings in shares of argenex by 32.1% in the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after purchasing an additional 122 shares during the last quarter. NewEdge Advisors LLC increased its position in shares of argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares in the last quarter. Focus Partners Wealth lifted its holdings in argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after purchasing an additional 73 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in argenex by 60.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.